SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
3d rendered illustration of hockey ice rink and goal. The puck is flying on goal.
Immunology and inflammation
Novartis, Vertex, More Optimizing Shots on Multiple Goals in Lucrative I&I Space
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the third quarter, the pipeline-in-a-product strategy has never been more attractive.
November 12, 2025
 · 
6 min read
 · 
Heather McKenzie
Podcast
Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers
Pfizer seals the deal with Metsera for $10 billion after Novo Nordisk bowed out; President Donald Trump welcomes executives from Novo and Eli Lilly to the White House to announce that the companies’ GLP-1 medicines would be sold at a reduced cost; and the FDA grants the second round of priority review vouchers—primarily to already marketed drugs.
November 12, 2025
 · 
1 min read
 · 
Heather McKenzie
Various white pills and capsules forming a map of the world, illustrating humanity's increasing dependency on medication manufacturing.
Drug pricing
How Effective Will TrumpRx and Other Direct-to-Consumer Drug Pricing Initiatives Be?
With pricing pressures climbing, Pfizer, Eli Lilly and other major drugmakers are looking to sell their products directly to patients. Analysts are skeptical that these efforts, including those announced to much fanfare from the White House, will result in meaningful reductions in drug spending.
November 12, 2025
 · 
11 min read
 · 
Tristan Manalac
Silver Spring, MD, USA 11/10/2020: Exterior view of the headquarters of US Food and Drug Administration (FDA). This federal agency approves medications, vaccines and food additives for human use.
FDA
FDA Stalwart Pazdur Named Tidmarsh’s Replacement as CDER Director
The appointment of Richard Pazdur, currently director of the FDA’s Oncology Center of Excellence, comes less than a week after he reportedly declined the post, and just nine days after his predecessor’s controversial exit.
November 11, 2025
 · 
1 min read
 · 
Heather McKenzie
3d rendering medical heart in yellow background
Cardiovascular disease
Amgen, Merck, Novo, More Take Cardiovascular Benefits to New Heights at AHA 2025
Data presented at this year’s American Heart Association Scientific Sessions in New Orleans underline rapid advancements in the cardiovascular field.
November 11, 2025
 · 
5 min read
 · 
Tristan Manalac
Unhappy young woman feel lonely abandoned in crowd suffer from communication lack. Upset girl struggle with depression or mental disorder. Psychological problem. Flat vector illustration.
Depression
Neurocrine’s Depression Drug Delivers ‘Surprise’ Phase II Miss
The mid-stage failure was unexpected to analysts at BMO Capital Markets, who viewed ‘770 as mostly derisked given its similar mechanism of action to Johnson & Johnson’s Spravato.
November 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Changing or transforming, turning around, challenging the odds and conquering adversity, a businessman pole vaulting from the down arrow to the up arrow of growth
Cancer
Cogent Hits ‘Unprecedented’ Efficacy in Rare Stomach Cancer, Clearing Path to FDA
Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next year after what Leerink said was “the first positive trial in this disease in over a decade.”
November 11, 2025
 · 
2 min read
 · 
Tristan Manalac
factory of the pharmaceutical industry. pills on the conveyor
Manufacturing
Drugmakers Push FDA To Extend Support to Existing Facilities
Representatives from companies such as Sanofi and Forge Biologics point to the potential for PreCheck to drive activation of idle production capacity and help companies that are already building plants.
November 11, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Illustration showing large scissors cutting employees in half
Layoffs
Kezar Loses 70% of Staff After FDA Cancels Meeting on Autoimmune Asset
Kezar Life Sciences suffered multiple clinical holds and four patient deaths in a trial testing zetomipzomib for lupus—a program that has since been canned. The company is still pursuing development in autoimmune hepatitis, but recent FDA communications could delay its timeline.
November 10, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS